Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. - Wikidata - awgldk - TriplyDB

Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.

Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.

http://www.wikidata.org/entity/Q35226178

about

Regeneration of stalled immune responses to transformed and infected cells using γδ T cells What lessons can be learned from γδ T cell-based cancer immunotherapy trials?The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy γδ T Cell Immunotherapy-A Review Adoptive cell therapy for sarcoma γδ T cells for cancer immunotherapy: A systematic review of clinical trials Harnessing the power of Vδ2 cells in cancer immunotherapy γδ T cells in cancer immunotherapy Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.Clinical applications of gamma delta T cells with multivalent immunity.A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?The anti-tumour effects of zoledronic acid Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells.Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation Potential of human γδ T cells for immunotherapy of osteosarcoma.Quantitative peripheral blood perturbations of γδ T cells in human disease and their clinical implications.Hunting for clinical translation with innate-like immune cells and their receptors.γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy.Cancer Immunotherapy Using γδT Cells: Dealing with Diversity.Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing.Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity.Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2(+) γδ T cell cytotoxicity in a perforin-dependent manner.Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.Apoptosis Induced via Gamma Delta T Cell Antigen Receptor "Blocking" Antibodies: A Cautionary Tale Current Advances in γδ T Cell-Based Tumor Immunotherapy.Gamma-delta (γδ) T cells: friend or foe in cancer development?Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti- versus Pro-Tumoral Activities.Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.

P2860

Q26823185-5270B820-5F1C-4951-8F9C-A7EF49F66403 Q26849323-FC917830-BBB9-4661-8180-D60752101B2C Q26859775-FDA24686-A62A-42AD-92EC-B2A072DCAD1E Q26995102-EB3DE38D-1D4F-4AB3-975D-19DE5238B62D Q27009541-DEA55C9E-004D-47D7-A0AA-DB92B531533E Q27021705-C189FD5C-59A6-4BC7-9006-D26318843C28 Q27027547-94F69670-B17D-483C-A386-202D165861B1 Q28068988-2B0FD0B8-AF27-405E-9767-F7A818A6A6C4 Q28085397-34B44BB7-EBE3-47DB-980D-65AD8B869D7C Q33920919-F279BC47-1761-46A8-A281-033E18A1D497 Q34517192-0539D6FC-4A64-4667-ACED-96C9E4D62BC5 Q34560345-5108F0F2-35C4-4F15-98A3-CA2CAADCCA28 Q34677859-6C610ACA-A994-4F24-8FC1-3F6910F11FE6 Q34743969-48B3D1E5-23FA-4B81-8FC6-EE93E02BC0A7 Q35654544-D85B6F78-AC58-4D87-8490-8A1788AD4803 Q35799192-A3E06725-FDF5-4591-A087-AB487585C5E5 Q36491653-D1A1FE06-D6B2-48FB-96DE-37369FFF6564 Q36597374-7CA1B0D2-9985-4BE9-A44F-DBC79CF28BB1 Q36803818-421427AC-4AE4-4953-8325-E18661B16AA4 Q37127038-D4E3D517-C7B9-4958-8FAB-13B2C20BBCA8 Q37333126-C630B103-E5DB-4806-BAB6-91FEB0C2D254 Q37354985-C89B06A4-0D70-4499-B7DC-ACD05F9EF7E1 Q37605828-1415D0D4-66E9-4964-8988-5C46D8872221 Q37655345-67584D73-3F65-470F-93CB-CB74B6375F65 Q38052064-50F71F84-62C5-4D09-BAB9-B6712212DDF4 Q38152686-202F247C-0E48-447A-9AC3-0A6BE59DE02E Q38171917-6C639AFA-213F-487C-89C2-4EB00E6DB481 Q38271585-2C713B7F-1EFE-4146-BDEA-B6F83D026096 Q38283536-9028180E-7A82-4AB5-8D76-27A098B86A85 Q38787725-23D410E0-FC51-475C-B38C-DA504AA8A019 Q38986536-956965B6-EE0C-4F06-8793-0CD99BBD0290 Q39396311-717944A0-B822-496C-9F3D-B57AE7762AAC Q39424272-79E1652D-7A33-44E3-8933-2E234060A104 Q40213985-ED5B1498-664D-44E6-996E-4189FA99DB94 Q40252845-FC6D9A3F-76EC-4FAE-8C92-58DEE18B5FA4 Q40989863-0DB28AF3-1796-40F9-8D18-1341C7D89017 Q47100174-0C74C03A-2975-4F98-B1C0-4E60CA5BCC8C Q47742552-CB668E58-075F-4F8E-818B-77BB57AD5B8F Q50144881-B9452420-1F22-427E-A4A1-072B3A98B29D Q50932570-9F084EBC-88D3-43D3-BDA6-C5197E93B9C9

P2860

Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.

http://www.wikidata.org/entity/Q35226178

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pilot trial of interleukin-2 a ...... fractory renal cell carcinoma.

@ast

Pilot trial of interleukin-2 a ...... fractory renal cell carcinoma.

@en

type

label

Pilot trial of interleukin-2 a ...... fractory renal cell carcinoma.

@ast

Pilot trial of interleukin-2 a ...... fractory renal cell carcinoma.

@en

prefLabel

Pilot trial of interleukin-2 a ...... fractory renal cell carcinoma.

@ast

Pilot trial of interleukin-2 a ...... fractory renal cell carcinoma.

@en

P1433

Q35226178-8C5F61B2-B337-4830-AFC6-47773FA6C31D

P1476

Q35226178-2C4D206B-354F-4AA7-9004-9006A6C1C33A

P2093

Q35226178-19CE4B7C-2025-4A53-844C-88AE19A34A21

Q35226178-2C108550-777A-4754-BA9E-43390E153133

Q35226178-6574C915-0C3E-47D5-9CAC-21BC41800AB4

Q35226178-6D7EE38C-AF9D-410C-BC2E-70E215FEBE2F

Q35226178-7DC09FF6-20A2-442E-8DBD-F942A9B4B945

Q35226178-81FCAF1C-48C9-4978-AE31-31DA9709FEDA

Q35226178-97B87156-47EE-4BB2-9EE3-5171D54C32E6

Q35226178-BC073A47-A2DC-4706-8B7C-7BD674AE43F6

Q35226178-BF49610F-F7D1-4F2D-B8B8-458DAD8F5FA9

P2860

Q35226178-0A8256AB-F7EB-48E0-858E-A136E2C98ABB

Q35226178-0BE5DAA9-D222-418D-8DE9-9ABA091335B5

Q35226178-1279273C-0B53-4ADC-918F-D2BCDB6578C9

Q35226178-16D616AF-E889-442A-9FE3-7BA9C76F36DB

Q35226178-170B7319-91EF-4E11-9392-CEFEBBC77469

Q35226178-249AAB38-99F9-442E-9FEA-65B3802FBF52

Q35226178-2929AE18-EA08-4252-9079-D7F9C1949271

Q35226178-2E9E3111-DC8D-4216-93B2-E8CCE31B0347

Q35226178-337802C7-C03E-4EC2-9B9D-991CE839AAEB

Q35226178-33A6A11C-3EC6-4A79-B3E0-60B6520A79A7

P2888

Q35226178-EE5883A5-54DA-4E41-B268-189AD518DA73

P304

Q35226178-7B39F70E-D5CF-4765-AFBE-BB4E1B213EC4

P31

Q35226178-83B736A1-B4EE-41EA-A1BF-BA1BC3EF23C8

P356

Q35226178-60ACC249-CCB6-4553-ADE6-76E82729F893

P433

Q35226178-95A76172-4702-4BD9-B6EF-1EB5AD31B011

P478

Q35226178-3580B287-04BE-4906-AD9D-80B5F7D366A1

P50

Q35226178-BC731A19-98F1-427D-A0D6-5732AD518D9E

P577

Q35226178-D26D6F28-9491-454D-9A7B-DC624190F883

P5875

Q35226178-164FF16D-5B11-4C6A-8FFF-36F974DE7161

P698

Q35226178-AEAB9A3F-128B-4CB4-8E0A-1C649F554400

P932

Q35226178-4526FAAD-4555-421C-BE4A-0F530BB60894

P356

S00262-011-1049-8

P1433

Cancer Immunology, Immunotherapy

P1476

Pilot trial of interleukin-2 a ...... fractory renal cell carcinoma.

@en

P2093

Dorothea L Horvath

http://www.w3.org/2001/XMLSchema#string

Douglas G McNeel

http://www.w3.org/2001/XMLSchema#string

Glenn Liu

http://www.w3.org/2001/XMLSchema#string

Jens C Eickhoff

http://www.w3.org/2001/XMLSchema#string

Joshua M Lang

http://www.w3.org/2001/XMLSchema#string

Mahazarin R Kaikobad

http://www.w3.org/2001/XMLSchema#string

Marianne Wallace

http://www.w3.org/2001/XMLSchema#string

Mary Jane Staab

http://www.w3.org/2001/XMLSchema#string

Miroslav Malkovsky

http://www.w3.org/2001/XMLSchema#string

P2860

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

Cancer statistics, 2010

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Lenalidomide therapy for metastatic renal cell carcinoma.

P2888

s00262-011-1049-8

P304

1447-1460

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-011-1049-8

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51197796

http://www.w3.org/2001/XMLSchema#string

P698

21647691

http://www.w3.org/2001/XMLSchema#string

P932

3177972

http://www.w3.org/2001/XMLSchema#string